Ainos, Inc. quarterly report, Q2 FY2017

Business context and reporting period

The supplied filing is Amarillo Biosciences, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2017; this does not match the request metadata naming Ainos, Inc. The company develops low-dose oral interferon products and is pursuing additional medical and consumer-product businesses. Its Medical Division opened a diabetes treatment center in Hong Kong in February 2017 and reported APT equipment sales; it was preparing centers in Taiwan.

Financial results and position

At June 30, cash was $69,376, versus $134,125 at December 31, 2016. Current assets were $156,807 and current liabilities were $1,234,728, a reported working-capital deficit of $1,077,921. Total liabilities were $1,234,728, including $791,481 in demand convertible notes payable to related parties and a $70,000 related-party note. Stockholders’ deficit was $871,472. The company reported $120,625 of financing cash inflows in the first half, including $50,625 from an equity placement and $70,000 from a related-party note.

Material changes versus the prior comparable period

Second-quarter revenue was $250,502, all from APT equipment sales, versus no revenue in the prior-year quarter; net income was $13,024 versus a $136,224 loss. For the first half, revenue rose from $4,400 to $250,502, while net loss narrowed from $257,865 to $175,948. First-half SG&A increased 42% to $361,948, mainly due to salary expense; interest expense increased to $5,701 from $1,459. First-half operating cash use improved to $159,588 from $325,120, but cash declined by $64,749 during the period.

Outlook, risks, contingencies and unusual items

Management stated that the company had not achieved sustained operating income and that substantial doubt existed about its ability to continue as a going concern. It estimated funding needs of $1.0 million to $1.6 million for its core technology and proposed new revenue streams; meaningful revenue from these efforts was not expected before the final quarter of 2017 or later. Management said the Yang Group had indicated willingness to assist with future financing, but no assurance of funding was provided. The company warned that failure to obtain financing could force it to cease operations.

Commercialization risks include the discontinued supply of human interferon, potentially lengthy sourcing, testing and FDA approval, and patents nearing expiration. The company also cited uncertainty over clinical trial results, regulatory approvals, trial costs, patient enrollment, commercial partnerships and future financing. It reported no research and development expense in either comparative period. No legal proceedings or claims were known to the company as of the report date.

Disclosure controls and procedures were deemed ineffective. Management identified material weaknesses involving insufficient technical accounting expertise and personnel, lack of segregation of duties, and inadequate controls over authorization and documentation of revenue and equity transactions. The filing reports related-party transactions, including management stock compensation and notes payable; investors should review their terms and governance implications.

Important facts for investors to verify

• Confirm the registrant’s identity: the provided document is for Amarillo Biosciences, Inc., not Ainos, Inc.
• Assess the company’s liquidity, near-term financing requirements and the basis for management’s going-concern warning.
• Verify the sustainability and collectability of APT equipment revenue and whether the planned Taiwan centers become operational.
• Review related-party debt, advances, stock compensation and the uncompleted related-party stock subscription.
• Track remediation of the disclosed material weaknesses and the status and remaining life of key patents and interferon supply.